Gitlab Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? Gitlab Inc trades at $53.03 (market cap $8.66B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Gitlab Inc and Hinge Health Inc. Class A Common Stock are close in size by market cap, and Hinge Health Inc. Class A Common Stock is more actively traded (879,799 versus 9,356,692). Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| GTLB | HNGE | |
|---|---|---|
Market Cap | $8.66B | $8.48B |
Volume | 9,356,692 | 879,799 |
Sector | Technology | Health |
52-Week High | $56.01 | $105.14 |
52-Week Low | $19.42 | $31.17 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $7.40B | $8.10B |
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $53.16, down 5.09% today but remains near its 52-week high territory. The stock shows strong technical momentum with bullish moving averages despite overbought RSI readings. Fundamentally, revenue growth remains robust at 21.3% year-over-year (Q2 2026 earnings), though profitability remains elusive with negative net margins. Recent earnings beats and raised guidance have fueled positive sentiment, with the company benefiting from AI-driven demand in software development pipelines.
Outlook: GitLab's AI integration and strong execution position it for continued growth, but high valuation multiples (P/E 521) and persistent losses present risks. Analyst consensus leans Hold with $49.71 target, suggesting limited near-term upside from current levels. Key catalysts include Q3 earnings and AI product adoption, while competition and macroeconomic pressures remain headwinds.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →